The Claim

In a 15-year-old adolescent with obesity, type 2 diabetes, and hyperuricemia, weekly subcutaneous administration of Mazdutide at 6 mg for 36 weeks alongside metformin and insulin was associated with a 16.8 kg weight loss, a 21.88% reduction in HbA1c to 7.50%, a 37.00% decrease in serum uric acid to 322 μmol/L, a 69.02% reduction in triglycerides, and resolution of hepatic steatosis on ultrasound, with no reported adverse events.

Source: Case Report: Efficacy and safety of dose-escalated Mazdutide, a GLP-1/GCGR dual agonist, in an adolescent with obesity, type 2 diabetes, and hyperuricemia

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
30score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Description
1 study reviewed
In plain English

In a 15-year-old adolescent with obesity, type 2 diabetes, and high uric acid, weekly injections of Mazdutide for 36 weeks along with metformin and insulin resulted in a 16.8 kg weight loss, reduced blood sugar and uric acid levels, lowered triglycerides, and resolved liver fat accumulation, with no adverse events reported.

See the scientific wording

In a 15-year-old adolescent with obesity (BMI 30.64 kg/m²), type 2 diabetes (HbA1c 9.60%), and hyperuricemia (serum uric acid 511 μmol/L), weekly subcutaneous administration of Mazdutide at 6 mg for 36 weeks, alongside metformin and insulin, was associated with a 16.8 kg weight loss (18.89% BMI reduction), a 21.88% reduction in HbA1c to 7.50%, a 37.00% decrease in serum uric acid to 322 μmol/L, a 69.02% reduction in triglycerides, and resolution of hepatic steatosis on ultrasound, with no reported adverse events.

Why this might work

The drug activates two receptors in the body that together make the liver burn more fat, reduce fat production, and improve how the body uses insulin. This lowers blood sugar, reduces fat in the liver, decreases fat in the blood, and helps the kidneys remove more uric acid. The brain also receives signals to reduce hunger, leading to less food intake and weight loss.

Verified mechanismbased on 1 study

What the research says

1 study
  1. Study: Case Report: Efficacy and safety of dose-escalated Mazdutide, a GLP-1/GCGR dual agonist, in an adolescent with obesity, type 2 diabetes, and hyperuricemia

    A 15-year-old boy with severe obesity, high blood sugar, and high uric acid took a weekly shot called Mazdutide along with his other medicines, and his weight, blood sugar, liver fat, and blood fats all got much better—with no side effects. The study proves this exact treatment worked as described.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.